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ACEI-RA is becoming a relatively common 
side effect, which has the potential to be seen 
in all clinical settings. Regarding bedside 
nursing, it is important to be able to promptly 
recognize the signs and symptoms of ACEI-RA, 
knowing that these patients will not present 
with itching, uticaria, et cetera, which are 
typically seen with allergic reactions (Cosco & 
Winawer, 2015). In the emergency 
department, nursing staff needs to be able to 
identify these patients as critical and 
immediately notify a healthcare provider 
about the patient. 
Otterbein University, Westerville, Ohio
Implications for 
Nursing Care
ACEIs are highly effective for 
treating several chronic diseases that 
would otherwise have a much higher 
morbidity and mortality rate (Chua et 
al., 2011). Despite the positive benefits 
of this medication class, the deleterious 
effects of angioedema warrants vigilant 
screening of patients taking ACEIs by 
healthcare providers and promoting 
awareness in patients and close family 
members, if possible. The author strives 
to bring awareness to the signs, 
symptoms, and underlying 
pathophysiologic process of ACEI-RA.  
Conclusion
Signs & Symptoms 
Angiotensin-converting enzyme 
inhibitor (ACEI) medications are one of 
the leading causes of angioedema in 
the United States, also known as ACEI-
RA (Chan & Soliman, 2015). ACEI 
medications are frequently prescribed 
to help manage diseases, such as 
hypertension and congestive heart 
failure, and include, but are not limited 
to lisinopril and enalapril, with 
lisinopril being the most commonly 
prescribed at this time (Chan & 
Soliman, 2015). In addition, ACEIs are 
used to help prevent myocardial 
infarction, diabetic neuropathy, and a 
cerebrovascular accident (Chua, 
Ignaszewski, & Schwenger, 2011).  
According to Loftus et al. (2014), 
about 40 million people were taking 
ACEIs in 2000, with ACEI-RA resulting 
in only “0.1%-6% of cases” (p. 2506). 
Less than six percent sounds like a 
rather small number; however, with 
such a large population taking ACEIs, 
the potential cases of related 
angioedema amount upwards to two 
million patients (Loftus et al., 2014). 
There are several risk factors for 
developing ACEI-RA, with the greatest 
at risk group being African-American 
females, who are “three times more 
likely to develop ACEI-RA” (Spencer, 
2016, p. 41). A list of known risk 
factors for developing ACEI-RA is 
provided in the next section. The 
length of time taking an ACEI does not 
determine if or when angioedema will 
occur. In a study by Chan and Soliman 
(2015), one patient took an ACEI for 
nearly 20 years without any signs of an 
adverse reaction, when that individual 
suddenly developed angioedema as a 
result of the ACEI. 
The author of this research project 
has chosen angioedema caused by 
ACEI medications because it is seen 
frequently in the emergency 
department, which is the author’s 
current area of practice. 
Understanding ACE-RA is important for 
all involved in direct patient care, 
particularly emergency medicine and 
those who have prescription 
privileges. When prescribing a drug 
from this class, one must understand 
the pharmacokinetics of ACEIs in the 
human body and the particular 
patient’s risk factors for developing 
angioedema, then weigh the risks 
versus benefits in order to provide the 
best possible care to patients. 
The following are possible signs and symptoms associated with ACEI-RA, 
with a cough being one of the first symptoms a patient may notice, and 
should be a warning sign to healthcare providers that the patient may be 
experiencing a potential reaction to the ACEI (Chan & Soliman, 2015, p. 92). 
Also, potential risk factors for developing ACEI-RA are provided below 
(Wadelius et al., 2014, p. 479).
ACEI-RA is not considered a true allergic 
reaction, but is rather a potentially life threatening 
side effect from taking an ACEI (Chan & Soliman, 
2015). A true allergic reaction is one that involves 
IgE antibodies, which ACEI-RA does not (Spencer, 
2016). Angiotensin-converting enzyme (ACE) is an 
enzyme in the human body that helps to control 
and limit the manufacturing of bradykinin (Gang et 
al., 2013). It does so by blocking angiotensin I from 
converting to angiotensin II, which has 
vasoconstrictive activity in the body (Knecht, Dunn, 
& Macaulay, 2014).  This process is part of a more 
complex system in the human body, known as the 
renin-angiotensin-aldosterone system (RAAS) 
(Fagyas et al., 2014). An algorithm is provided 
below, outlining the RAAS in further detail.
Bradykinin is involved in the innate immune 
system and works by causing vasodilation, and 
when left unchecked, ultimately results in 
angioedema (Maurer et al., 2011). When the 
activity of ACE is inhibited, bradykinin is able to 
accumulate, thus explaining why these 
medications can results in inadvertent angioedema 
(Gang et al., 2013). Untreated, ACEI-RA will resolve 
on its own within hours to days and is self-limiting, 
however, the potential for respiratory compromise 
leading to respiratory arrest is very high 
(Rasmussen, Mey, & Bygum, 2014). 
Understanding the pathophysiology 
behind ACEI-RA is key to deciding a plan of 
care in order to resolve the patient’s signs 
and symptoms, and prevent possible 
intubation or tracheostomy placement. 
While medications such as 
diphenhydramine, famotidine, 
epinephrine, and/or steroids are typical 
treatments for true allergic reactions, 
these medications are ineffective for ACEI-
RA, because it is not mediated by IgE or 
histamines (Gang et al., 2013). A 
medication called icatibant, which is 
administered only once subcutaneously at 
a dose of 30 mg, has proven to be 
extremely successful in treating ACEI-RA 
(Scalese & Reinaker, 2016). It blocks the 
receptor for bradykinin at the B2 receptor 
site. In doing so, the vasodilator effects of 
bradykinin are rendered completely 
ineffective, thus reducing the swelling and 
other associated symptoms. 
According to Scalese and Reinaker
(2016), icatibant works within minutes of 
administration and can prevent invasive 
procedures that otherwise, may be needed 
to ensure an effective airway. 
Underlying 
Pathophysiology
Signs & Symptoms
Cough
Swelling (may be unilateral)
o Face
o Lips
o Tongue 
o Floor of mouth
o Larynx
Shortness of Breath
Difficulty Swallowing
Drooling
Hoarse Voice
(Thompson, 2010a)
Renin-Angiotensin-Aldosterone System (RAAS)
(Bpac.org, 2016)
Risk Factors 
Female Gender
African American
History of Angioedema
Advanced Age
Chronic Diseases (such as, heart failure, diabetes mellitus, coronary 
artery disease 
Hoarse Voice
(Thompson, 2010b)
Advanced practice nurses, 
particularly those who have prescriptive 
authority, need to be aware of the risk 
factors associated with developing ACEI-
RA and regularly screen patients taking 
an ACEI for early warning signs, such as 
a chronic cough. If the risk for 
developing ACEI-RA is too high, the 
prescribed may want to consider an 
alternative drug. All patients taking 
ACEIs need to be thoroughly educated 
about the signs and symptoms of ACEI-
RA and what to do if he/she notices any 
of them. Lastly, all clinical healthcare 
professionals need to be aware that 
ACEI-RA is not an allergic reaction and 
should not be treated as such. 
Medications, such as icatibant, should 
be used if available to improve patient 
outcomes. 
One noteworthy downside to icatibant is 
its’ cost, which is approximately $10,000 to 
$12,000 (Scalese & Reinaker, 2016). However, 
the author’s perspective is that the cost of this 
drug is significantly less than an intensive care 
unit admission, in addition to several other 
treatments and drugs that may be needed if 
angioedema is not quickly reversed. Other 
treatments that have proven to be less 
effective, but are worth considering if icatibant 
is unavailable are fresh frozen plasma and C1 
inhibitors (Scalese & Reinaker, 2016). 
